Application of TCT and Human Papillomavirus (HPV) in Screening for Cervical Lesions in the South of Sichuan Province, China
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3662
Abstract
Objective: To explore the role of thin prep liquid-based cytology test (TCT) and human papillomavirus (HPV) genotyping detection in early diagnosis of cervical lesions, and assess the distribution of HPV subtypes among women in southern Sichuan. Methods: The results of TCT and HPV detection last 5 years were analyzed, and compared with the clinical pathological examination of 1126 cases. Results: The TCT-positive rate was 3.22% (2435/75512), including atypical squamous cells of undetermined significance (ASC-US) 1410 cases, atypical squamous cells cannot exclude HSIL (ASC-H) 388 cases, low-grade squamous intraepithelial lesions (LSIL) 301 cases, high-grade squamous intraepithelial lesion (HSIL) 300 cases, squamous cell carcinomas (SCC) 14 cases, atypical glandular cell (AGC) 19 cases, and adenocarcinoma 3 cases. With increase of pathological diagnosis grade, the grade of cervical cytology increased (P﹤0.001). 12.74% (508/3989) of women were tested HPV positive, the most frequently detected high-risk types (HR-HPV) and low-risk types (LR-HPV) were HPV 52, 16, 58, 33 and HPV 6, 11, 43, respectively. Overall HPV infection rate was high among 50 ~ 59 and 20 ~ 29 age group. With the grade of pathological diagnosis increasing, the positive rate of HPV infection also rose (P﹤0.001). Conclusion: TCT with HPV genotyping technology can significantly increase the detection rate of high grade cervical lesions. The most common HR-HPV types were HPV 52, 16, 58, 33, and LR-HPV types were HPV 6, 11, 43. HPV prevalence showed a bi-modal age in southern Sichuan.
Keywords
Cervical lesions; Thin prep liquid-based cytology test; Human papilloma virus; Histopathology; Southern Sichuan.
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1]Sharma S, Deep A, Sharma AK. Current Treatment for Cervical Cancer: An Update. Anticancer Agents Med Chem 2020; 20(15): 1768-1779.
[2]Wang JL, Yang YZ, Dong WW, Sun J, Tao HT, Li RX, et al. Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev 2013; 14(5): 2979-2982.
[3]Chen H, Shu HM, Chang ZL, Wang ZF, Yao HH, Zhu HM, et al. Efficacy of Pap test in combination with ThinPrep cytological test in screening for cervical cancer. Asian Pac J Cancer Prev 2012; 13(4): 1651-1655.
[4]Apgar BS, Zoschnick L, Wright TC Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003; 68(10): 1992-1998.
[5]Maniar KP, Nayar R. HPV-related squamous neoplasia of the lower anogenital tract: an update and review of recent guidelines. Adv Anat Pathol 2014; 21(5): 341-358.
[6]Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health 2021; 21(1):1329.
[7]Liang H, Fu M, Zhou J, Song L. Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening. Oncol Lett 2016; 12(2): 887-892.
[8]Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, et al. Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China. Virol J 2022; 19(1):146.
[9]Wang Y, Yu YH, Shen K, Xiao L, Luan F, Mi XJ, et al. Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev 2014; 15(2): 671-676.
[10]Tao X, Austin RM, Zhang H, Zhang L, Xiao J, Wang L, et al. Pap Test Reporting Rates for Conventional Smear and Liquid-Based Cervical Cytology from the Largest Academic Women's Hospital in China: Analysis of 1,248,785 Pap Test Reports. Acta Cytol 2015; 59(6): 445-451.
[11]Lu Z, Chen J. [Introduction of WHO classification of tumours of female reproductive organs, fourth edition]. Zhonghua Bing Li Xue Za Zhi 2014; 43(10): 649-650.
[12]Zhang W, Guo N, Li B, Shang E, Wang J, Zhang M, et al. Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020. Virol J 2023; 20(1):11.
[13]Jing L, Zhong X, Zhong Z, Huang W, Liu Y, Yang G, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis 2014; 41(12): 732-738.
[2]Wang JL, Yang YZ, Dong WW, Sun J, Tao HT, Li RX, et al. Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev 2013; 14(5): 2979-2982.
[3]Chen H, Shu HM, Chang ZL, Wang ZF, Yao HH, Zhu HM, et al. Efficacy of Pap test in combination with ThinPrep cytological test in screening for cervical cancer. Asian Pac J Cancer Prev 2012; 13(4): 1651-1655.
[4]Apgar BS, Zoschnick L, Wright TC Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003; 68(10): 1992-1998.
[5]Maniar KP, Nayar R. HPV-related squamous neoplasia of the lower anogenital tract: an update and review of recent guidelines. Adv Anat Pathol 2014; 21(5): 341-358.
[6]Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health 2021; 21(1):1329.
[7]Liang H, Fu M, Zhou J, Song L. Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening. Oncol Lett 2016; 12(2): 887-892.
[8]Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, et al. Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China. Virol J 2022; 19(1):146.
[9]Wang Y, Yu YH, Shen K, Xiao L, Luan F, Mi XJ, et al. Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev 2014; 15(2): 671-676.
[10]Tao X, Austin RM, Zhang H, Zhang L, Xiao J, Wang L, et al. Pap Test Reporting Rates for Conventional Smear and Liquid-Based Cervical Cytology from the Largest Academic Women's Hospital in China: Analysis of 1,248,785 Pap Test Reports. Acta Cytol 2015; 59(6): 445-451.
[11]Lu Z, Chen J. [Introduction of WHO classification of tumours of female reproductive organs, fourth edition]. Zhonghua Bing Li Xue Za Zhi 2014; 43(10): 649-650.
[12]Zhang W, Guo N, Li B, Shang E, Wang J, Zhang M, et al. Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020. Virol J 2023; 20(1):11.
[13]Jing L, Zhong X, Zhong Z, Huang W, Liu Y, Yang G, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis 2014; 41(12): 732-738.
Copyright © 2025 Xiaoqin Tang, Dingyao Jiang, Yuhan Wang, Sibei Ruan, Mingxi Tang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
